Following the European Parliament elections which took place last month, and as the new European legislative term begins, Alzheimer Europe is re-issuing an urgent call to European and national organisations and other entities to endorse the “Helsinki Manifesto”. This Manifesto outlines the current situation in relation to dementia across Europe and makes specific demands for the European Union (EU), as well as for national governments.
We are pleased to announce that the membership of the European Working Group of People with Dementia (EWGPWD) has been renewed and that the new incarnation of the group has officially begun its mandate. As of 15 July 2024, the group has voted in its Executive members, with Kevin Quaid (Ireland) becoming the group's new Chairperson and Lieselotte "Lilo" Klotz (Germany) its new Vice-Chairperson. Many congratulations to them both.
We are pleased to announce that the membership of the European Dementia Carers Working Group (EWGPWD) has been renewed and that the new incarnation of the group has officially begun its mandate. As of 15 July 2024, the group has voted in its Executive members, with Trevor Salomon (United Kingdom) becoming the group's new Chairperson and Sonata Mačiulskytė (Lithuania) its new Vice-Chairperson. Many congratulations to them both.
On 26 July 2024, the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the marketing authorisation application of Eisai for lecanemab for the treatment of early Alzheimer’s disease (AD). Alzheimer Europe regrets the decision of the EMA, and hopes that re-examination will result in an outcome that enables more Europeans living with early AD to access lecanemab in the future.
On 31 July 2024, the standing Lancet Commission on Dementia Prevention, Intervention, and Care published the results of their 2024 report, highlighting the potential for dementia risk reduction and prevention by tackling modifiable risk factors. During a dedicated session at the Alzheimer’s Association International Conference in Philadelphia, US, the Commission shared the main updates and changes from the 2020 report.
The Alzheimer’s Association International Conference (AAIC) 2024 took place in Philadelphia, US and online, between 28 July and 1 August. We share some selected highlights from the event and the research presented.
Alzheimer Europe's 
Following the European Parliament elections which took place last month, and as the new European legislative term begins, Alzheimer Europe is re-issuing an urgent call to European and national organisations and other entities to endorse the “Helsinki Manifesto”. This Manifesto outlines the current situation in relation to dementia across Europe and makes specific demands for the European Union (EU), as well as for national governments. 
We are pleased to announce that the membership of the European Working Group of People with Dementia (EWGPWD) has been renewed and that the new incarnation of the group has officially begun its mandate. As of 15 July 2024, the group has voted in its Executive members, with Kevin Quaid (Ireland) becoming the group's new Chairperson and Lieselotte "Lilo" Klotz (Germany) its new Vice-Chairperson. Many congratulations to them both.
We are pleased to announce that the membership of the European Dementia Carers Working Group (EWGPWD) has been renewed and that the new incarnation of the group has officially begun its mandate. As of 15 July 2024, the group has voted in its Executive members, with Trevor Salomon (United Kingdom) becoming the group's new Chairperson and Sonata Mačiulskytė (Lithuania) its new Vice-Chairperson. Many congratulations to them both. 
On 26 July 2024, the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the marketing authorisation application of Eisai for lecanemab for the treatment of early Alzheimer’s disease (AD). Alzheimer Europe regrets the decision of the EMA, and hopes that re-examination will result in an outcome that enables more Europeans living with early AD to access lecanemab in the future.
On 31 July 2024, the standing Lancet Commission on Dementia Prevention, Intervention, and Care published the results of their 2024 report, highlighting the potential for dementia risk reduction and prevention by tackling modifiable risk factors. During a dedicated session at the Alzheimer’s Association International Conference in Philadelphia, US, the Commission shared the main updates and changes from the 2020 report.
The Alzheimer’s Association International Conference (AAIC) 2024 took place in Philadelphia, US and online, between 28 July and 1 August. We share some selected highlights from the event and the research presented.